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A Systematic Review and Meta-analysis of
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Habib Davanloo has spent his career developing and teaching methods to accelerate dynamic psy-
chotherapy, including his technique of intensive short-term dynamic psychotherapy (ISTDP). Over
the past 20 years, outcome studies using this treatment have been conducted and published. We per-
formed a systematic review of the literature to obtain studies presenting ISTDP outcome data. We
found 21 studies (10 controlled, and 11 uncontrolled) reporting the effects of ISTDP in patients with
mood, anxiety, personality, and somatic disorders. Using the random-effects model, we performed
meta-analyses including 13 of these studies and found pre- to post-treatment effect sizes (Cohen’s d)
ranging from 0.84 (interpersonal problems) to 1.51 (depression). Post-treatment to follow-up effect
sizes suggested that these gains were maintained at follow-up. Based on post-treatment effect sizes,
ISTDP was significantly more efficacious than control conditions (d = 1.18; general psychopathol-
ogy measures). Study quality was highly variable, and there was significant heterogeneity in some
analyses. Eight studies using various measures suggested ISTDP was cost-effective. Within limita-
tions of study methodologies, this evidence supports the application of ISTDP across a broad range
of populations. Further rigorous and targeted research into this method is warranted. (HARV REV
PSYCHIATRY 2012;20:97–108.)
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INTRODUCTION
Psychodynamic psychotherapy concerns itself with identi-
fying and addressing unconscious emotions and processes
that result in a broad range of symptoms (anxiety, depres-
sion, and somatic) and character problems. By recognizing
these processes and working through the emotions and con-
tent, the patient can be freed of the effects of the past, be
able to form relationships, and come to experience reduced
symptoms.1
Short-termpsychodynamic psychotherapieshave been de-
veloped and researched over the past 40 years to allow more
efficient psychodynamic treatment of greater numbers of pa-
tients compared to longer-term psychoanalytic therapies.2
These treatments have been extensively investigated, in-
cluding about a dozen meta-analyses showing, in general,
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large effects (Cohen’s d > 0.80) that persist in follow-
up for mixed-,3 somatic-,4 depressive-,5 and personality-
disordered6 patients.
Dr. Habib Davanloo has been one of the main proponents
of short-term psychodynamic psychotherapy techniques.7
In the 1970s, he developed what he called short-term dy-
namic psychotherapy, a treatment with active interventions,
including the challenge and confrontation of defenses, in
order to mobilize underlying, unresolved emotions. This
early treatment was found to be clinically effective with
select patient populations—and up to 35% of psychiatric
outpatients.7 Patients presenting with low anxiety toler-
ance, major depression, or somatization, however, were not
suitable for this early version of the treatment approach.7
In the 1980s, Davanloo refined and augmented the method
to allow treatment of these more complex patients and
began referring to the treatment as intensive short-term
dynamic psychotherapy (ISTDP).8 This augmentation in-
cluded a process to first build anxiety tolerance, which he
termed the graded format.8,9 To extend the treatment to
patients with primarily primitive defenses, including pro-
jection and projective identification, Davanloo developed
a further preparatory phase of bringing about “multidi-
mensional” structural changes in unconscious anxiety and
defense.10 So extended, ISTDP can be used effectively in
a broad clinical population. In a six-year study by the
author, 86.3% of 342 consecutive referrals to an outpa-
tient psychiatric practice were considered candidates for
ISTDP.11
Davanloo described a set of typical events that lead to
rapid access to unconscious emotions—which he called a
central dynamic sequence. He found that by actively focus-
ing on unconscious feelings and on defenses used to avoid
those feelings, a set of complex feelings was activated. These
feelings included deep appreciation of, but also irritation
with, the therapist’s efforts: these complex transference feel-
ings hearkened back to attachments and feelings associ-
ated with interruptions to those attachments in the pa-
tient. When these mixed feelings were activated, anxiety
and defenses moved in to block the patient’s awareness of
them. With specific efforts, including challenge and “head-
on collision” with the resistances, the patient was turned
against his defenses, and these feelings were then expe-
rienced with visceral and cognitive components. Once the
feelings were experienced, the anxiety about the feelings
dropped abruptly, and the defenses were therefore reduced.
Davanloo discovered that this process mobilized a healing
force in the patient—which he called the unconscious thera-
peutic alliance—that produced linkages to, and mental im-
ages of, unconscious unresolved content.12 This process has
been called unlocking the unconscious, which is an expres-
sion that many patients use to describe this access to previ-
ously unprocessed emotions.8 The process of experiencing
these emotions and developing insight into the relation-
ship between the emotions, anxiety, and defenses is what
allows symptom reduction and behavioral change to take
place; anxiety, depression, and personality disorders are the-
oretically treatable with ISTDP to the extent that they tie
in to underlying unprocessed emotions. For details of the
treatment method, readers are referred to Davanloo’s latest
article.10
Starting in the 1970s, Davanloo studied ISTDP through
extensive use of video technology.13 By retrospectively ex-
amining videotapes from patients who responded to treat-
ment compared with those who did not, he was able to refine
his approach. He used a dismantling procedure in which
he left out or added in specific interventions with groups
of patients, and then followed up to examine the effects
of these interventions as ingredients of change. Davanloo
further used patients’ feedback—as provided by them view-
ing videotapes of their own treatment sessions—to inform
the development of ISTDP. He has thus emphasized de-
tailed, individual case–based study as the central vehicle
for training, research, and ongoing quality improvement in
ISTDP. Davanloo reported in his initial case series, pub-
lished in 1980, that 83% of 143 mixed psychiatric patients
responded to ISTDP with “symptomatic” and “personality”
changes that persisted in those followed up (for 2 to 9
years).7 However, the lack of standardized self-report mea-
sures in this series from the 1970s onward limits compar-
isons that can be made with subsequent empirical studies
of ISTDP.
Various researchers have examined and corroborated Da-
vanloo’s main findings. ISTDP begins with a specialized
assessment interview called a trial therapy. This therapy,
which provides a thorough evaluation of the client and
tests suitability for ISTDP, has been characterized and
evaluated.14−16 Early studies characterizing ISTDP found
it to be an active and involved process,17−19 with highly fo-
cused therapist activity consistent with exploring and con-
fronting self-defeating patterns.20 Further studies found
ISTDP outcomes to be linked to a reduction in patient de-
fenses and increased expressed affect21 and degree of emo-
tional mobilization.11,22
Despite Davanloo’s publication of the results from his
videotaped case series from the 1970s and 1980s,7 to our
knowledge no systematic review has been conducted to ex-
amine the effectiveness of ISTDP. The purpose of the present
article is therefore both to provide a comprehensive review of
the current empirical literature and to examine the effec-
tiveness of ISTDP through a meta-analysis of the available
outcome data.
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METHODS
Search Strategy
Following literature searches that we completed for
four recent meta-analyses of short-term psychodynamic
psychotherapy,3−6 we examined the full texts of all stud-
ies identified to determine whether they met our inclusion
criteria (see below). Two of the authors—both of whom are
experienced clinicians and researchers in psychodynamic
psychotherapy—independently reviewed articles to estab-
lish study eligibility. Disagreements were discussed, and
consensus reached. In order to identify any studies pub-
lished after the previous search dates and to detect studies
not meeting criteria for previous meta-analyses, we con-
ducted a search in PsycINFO and CINAHL without date
restrictions and using the following search terms: davan-
loo (146 hits), short-term dynamic psychotherapy (355 hits),
and intensive short-term dynamic psychotherapy (163 hits).
The search was repeated in MEDLINE, with the follow-
ing results: davanloo (15 hits), short-term dynamic psy-
chotherapy (119 hits), and intensive short-term dynamic
psychotherapy (8 hits). References from the articles iden-
tified were examined, in turn, for any additional refer-
ences. Finally, networks of psychodynamic psychotherapy
researchers were contacted to identify any new or forthcom-
ing publications.
Study Selection
We included any published article with outcome data on
short-term psychodynamic psychotherapy referencing Da-
vanloo’s books or technical articles in its description of
the treatment delivered. That treatment could have been
employed alone or alongside other variants of short-term
psychodynamic psychotherapy. We used broad selection
criteria—and included randomized, controlled trials (RCTs),
nonrandomized, controlled trials, and studies with natural-
istic designs—in order to allow the maximal identification
of data for review. Studies delivering treatment in both in-
dividual and group format were included. In addition, no
restrictions were applied with regard to the patient popula-
tion of the study or the time period, culture, or geographical
location in which it was conducted.
Meta-analysis
We conducted three different meta-analyses: (1) assessing
pre- to post-treatment change with ISTDP, (2) assessing
post-treatment to follow-up change with ISTDP, and
(3) assessing ISTDP versus control conditions. Effect
sizes (Cohen’s d) were computed for each of the primary
studies.23,24 Because correlations across time points were
generally not reported, we decided to use Cohen’s d for
both the repeated-measures comparisons and the indepen-
dent group comparisons, as recommended by Dunlop and
others.25 Pre- to post-treatment ISTDP effect sizes were
calculated by subtracting the average post-treatment score
from the average pre-treatment score and dividing the
result by the pooled standard deviations of both groups.
Post-treatment to follow-up ISTDP effect sizes were calcu-
lated by subtracting the average follow-up score from the
average post-treatment score and dividing the result by the
pooled standard deviations of both groups. The comparative
effect sizes of ISTDP with control groups at post-treatment
were calculated by subtracting the average score of the
alternative condition from the average score of the ISTDP
condition and dividing the result by the pooled standard de-
viation of both conditions. When data were not available to
calculate effect sizes, the study was excluded from the meta-
analysis. Effect sizes of 0.2 are considered small; effect sizes
of 0.5, moderate; and effect sizes of 0.8 or above, large.23
We used measures of general psychopathology, interper-
sonal functioning, depression, and anxiety as outcome cat-
egories. Only instruments explicitly measuring these con-
structs were used in the effect-size calculations. If more than
one instrument was used to assess a given outcome category
within a study (for example Hamilton and Beck depression-
rating scales in the same study), a mean effect size for the
different measures in this category was computed. We cal-
culated the pooled mean effect sizes and their confidence
intervals by means of the procedures implemented in the
computer program Comprehensive Meta-analysis (version
2.2.021; Biostat, Englewood,NJ,USA).We used the random-
effects model to compute pooled mean effect sizes, as consid-
erable heterogeneity of the included studies was expected.
The random-effects model results in broader 95% confidence
intervals (95% CI) and more conservative results.
To measure homogeneity, we calculated theQ-statistic. A
significant Q-value rejects the null hypothesis of homogene-
ity. We also calculated the I2-statistic, which is an indicator
of heterogeneity in percentages. A value of 0% indicates no
observed heterogeneity, and larger values show increasing
heterogeneity, with 25% indicating low, 50% indicating mod-
erate, and 75% indicating high heterogeneity.26
Furthermore, we conducted sensitivity analyses with re-
gard to study design (RCT vs. other), outcome analyses
(intention-to-treat [ITT] vs. completer only), and ISTDP
type (early [pre-1990] vs. later studies of ISTDP) to deter-
mine whether these factors bear on outcome. We hypoth-
esized that RCTs would have less robust effects, as would
studies with ITT analyses, and that the newer iterations of
ISTDP would have superior effects compared to earlier it-
erations. Because of the small number of studies included
in the meta-analyses, we did not conduct publication bias
analyses.
H
ar
v 
R
ev
 P
sy
ch
ia
try
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
V
rije
 U
niv
ers
ite
it A
ms
ter
da
m 
on
 05
/01
/12
Fo
r p
er
so
na
l u
se
 o
nl
y.
100 A. Abbass et al.
Harv Rev Psychiatry
March/April 2012
RESULTS
Description of Studies
Twenty-one papers reporting outcomes of Davanloo’s
ISTDP7,8,10,13 were identified for review (see Table 1).
Fifteen were identified through references from 4 recent
reviews of short-term psychodynamic psychotherapy,3−6
and we had knowledge of an additional 6 published studies.
The final sample consisted of 6 RCTs, 4 nonrandomized,
controlled trials, and 11 studies with no control groups. Two
studies incorporated a wait-list control,11,27 and 3 an active-
treatment comparison group.28,30,31 Eighteen of these stud-
ies employed individual ISTDP; 1 used ISTDP in a group
format;37 and 2 described a residential ISTDP program.36,44
Treatment was a mean of 18.0 (SD = 15.5) sessions
long.
A mean of 6.2 (SD = 8.6) therapists was involved per
study. Thirteen studies reported utilizing clinicians who
were well trained in ISTDP; three described therapists
with little or mixed experience; and three made no refer-
ence to therapist experience. Five studies utilized adherence
ratings, and seven reported treatment monitoring through
videotape supervision.
One study used blinded outcome evaluators,40 but the
others either did not blind the assessors or failed to report
on blinding. Two studies reported independently gathered
data on health care costs and utilization. ITT analyses were
conducted in nine studies, and the remaining studies used
completer-only analyses.
Treatment of Personality Disorders
Three RCTs of ISTDP for personality disorders have
been conducted.28,31,41 Hellerstein,31 Winston,28 and their
colleagues used Davanloo’s early technique7 to treat 25 and
15 patients, respectively, largely with diagnoses of Clus-
ter C personality disorders, including those not otherwise
specified.7 Treatments averaged 28.5 and 40.3 one-hour ses-
sions, respectively. At medium- to long-term follow-up (6–18
months), these studies reported a significant decrease in
symptoms following treatment. Hellerstein and colleagues31
did not find a significant reduction on the Inventory of In-
terpersonal Problems45 (IIP) (p = 0.10). However, Winston
and colleagues28 found that ISTDP significantly outper-
formed a wait-list control group on patients’ self-rated
target complaints (Target Complaints Questionnaire),46
symptoms (Symptom Checklist [SCL]–90),47 and the Social
Adjustment Scale.48 Both studies compared ISTDP to alter-
native short-term psychotherapies. Significant differences
on summary scales were not found between comparison
groups in these two studies.∗
Using Davanloo’s enhanced treatment13 with expe-
rienced therapists, Abbass and colleagues41 treated a
comparatively more severe population of patients, in-
cluding some with borderline, paranoid, and narcissistic
personality disorders. Following an average of 27.7 sessions,
those treated with ISTDP exhibited significantly improved
outcomes on symptom, interpersonal (IIP), and functional
measures in comparison to controls. When those in the
minimal-contact control group later received ISTDP of sim-
ilar length, similar gains accrued. Treatment gains were
maintained in long-term (mean = 2 years, 1 month) follow-
up. The ISTDP group evidenced significant reductions in
medication usage and an increase in employment rate and
work hours, whereas controls did not. This study reported
more efficient treatment of a broader range of patients
with personality disorders compared to studies of the early
version of ISTDP (Winston et al.;28 Hellerstein et al.31): the
patients in the study by Abbass and colleagues41 showed
superior gains on the IIP (vs. Hellerstein et al.31) and
SCL-90 (vs. Winston et al.28), required treatment for less
time (one-third shorter than in Winston et al.28), and rep-
resented a broader range of personality disorder categories
(vs. both Winston et al.28 and Hellerstein et al.31).
Cornelissen and Verheul36 reported case-series data from
a residential treatment program for personality disorders,
in which all patients received individual ISTDP sessions
in concert with group psychotherapy and different forms of
nonverbal therapy. Patients’ self-reported quality of inter-
personal relationships improved at discharge and increased
further both at 1-year and 3-year follow-up. The long-term
effects of all patients completing the program over the last
ten years have also been evaluated.44 From a naturalistic
sample of 155 patients, 69% were re-interviewed, with the
longest follow-up period being ten years. In that extended
sample, treatment effects calculated based on pre-treatment
and termination ratings were again in the large range on the
SCL-90 and also for general functioning.43 Comparison of
pre-treatment scores and those at longest follow-up revealed
that improvement in psychiatric symptoms was maintained
and that Global Assessment of Functioning49 scores signifi-
cantly improved (d = 1.5).
Four further studies included large proportions of pa-
tients with personality disorders.11,33,34,39 Two naturalis-
tic studies with sample sizes of 10 (all with personality
disorders) and 89 (over half with personality disorders),
∗The term significant and its variations are used throughout to
refer to statistical significance.
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respectively, saw scores on all outcome measures move
from the clinical to normal range in less than 15 hours
of treatment.34,39 Callahan33 reported selected naturalistic
data (n = 6) for patients with mixed Axis I and II diagnoses:
mean Global Assessment of Functioning ratings improved
significantly following treatment based on Davanloo’s early
treatment method.7 In a sample of 30 patients,15 87% hav-
ing personality disorders, the ISTDP trial therapy interview
(which has a treatment effect) brought significant gains on
all subscales and the global scale (GSI) of the Brief Symp-
tom Inventory50 (BSI), and the global IIP rating just failed
to reach significance (p = 0.06). When compared to a stan-
dard intake assessment, the ISTDP trial therapy format
demonstrated superior outcomes on the BSI-GSI and domi-
neering/controlling subscale of the IIP.16
Treatment of Somatic Symptoms
Six studies reported the use of ISTDP for somatic disor-
ders. In an RCT, Baldoni and colleagues29 studied ISTDP
compared to a medical treatment as usual control for ure-
thral syndrome and pelvic pain. Significant improvement in
urinary symptoms and pelvic pain was seen in those who
received ISTDP, with 70% of participants in remission at
four-year follow-up.29 ISTDP brought significant improve-
ment at termination and outperformed the control group on
target-symptom rating and measures of anxiety (p < 0.01),
depression (p < 0.05), and hostility (p < 0.05). At four-year
follow-up, however, only the latter two associations were
maintained.
A second RCT compared changes in immune factors in a
student population, following either six sessions of ISTDP
(n = 13) or a verbal-disclosure group setting (n = 14).32
Pre and post measurements found significant changes in
immune cell counts (CD4 and CD8) in the ISTDP group
relative to the control group.
Hinson and colleagues40 conducted a pre/post clinical
trial (n = 10) for psychogenic movement disorder. Assess-
ment at termination following nine completed treatments
showed significant changes on blinded ratings of movement
disorder51 and on self-report measures of anxiety, depres-
sion, and general functioning.
Three studies reported that ISTDP was effective in
reducing self-reported somatic symptoms.37,42,43 The first
study described an eight-week group ISTDP intervention to
promote the experiencing of repressed emotions for patients
suffering from chronic back pain.37 Pre/post data for 47
patients revealed significant changes in self-reported pain
scores but not in self-rated anxiety. In a second study,42
further analysis of pre-published case series data11 iden-
tified a subsample of 29 patients suffering from recurrent
headaches treated with ISTDP. This group received on
average 19.7 sessions. At termination, a significant drop
in psychiatric symptoms was found (p <.01), and service-
related cost savings were evident. Finally, ISTDP-based
assessment and treatment were provided to 50 patients
presenting to the emergency department with medically
unexplained symptoms.43 After an average 3.8 sessions
of ISTDP, significant symptom reduction (BSI-GSI and
somatization subscale) and a 69% drop in emergency
department visits per year were observed. By comparison,
a control sample of 27 patients referred to the service
who never received ISTDP treatment (for various reasons)
showed a nonsignificant 42% increase in emergency visits.
Other Psychiatric Disorders
Wiborg and Dahl30 used a randomized, controlled design to
examine the efficacy of clomipramine plus ISTDP versus
clomipramine alone for panic disorder. The authors found
that all patients receiving ISTDP were free of panic at-
tacks at termination, compared to 75% in the clomipramine
group. Eighty percent of patients in the ISTDP group re-
mained free of symptoms at 18-month follow-up versus 25%
receiving only clomipramine. When clomipramine was dis-
continued as part of the study, the relapse rate was high and
significantly greater in those who were not provided ISTDP.
Ninety-one percent of those with severe panic disorder pro-
vided clomipramine alone relapsed versus only 9% of those
provided ISTDP. ISTDP-treated patients also reported sig-
nificantly improved outcome on all symptom measures at
18-month follow-up.
In a large, naturalistic study of ISTDP, a mixed sample
of 166 patients was provided an average of 16.9 sessions.11
The sample as a whole was described as “fairly impaired,”
based on the rate of unemployment and nonresponse rate
to medications. After treatment, 86% and 65% of patients
no longer met clinical case criteria on the BSI and IIP, re-
spectively. Eighty-one percent of patients returned to work
following therapy, and 69% stopped all psychotropic med-
ications. A second article27 provided detailed clinical and
cost-effectiveness data for the 89 patients from this cohort11
for whom government-provided health care cost data were
available. Patients received on average 14.9 sessions, and
follow-up data one year post-termination were collected.
Large pre- to post-treatment effect sizes (d), ranging from
0.90 to 1.64, were seen on self-reported measures of symp-
tom distress51 and interpersonal difficulties.45
Two further case series offer preliminary data for ISTDP
in treating more complex psychiatric disorders.35,39 In
ten patients with treatment-resistant depression, ISTDP
showed large effects on self-rated depressive symptoms
(d = 2.52), clinician-rated depression (d = 3.9), and
interpersonal problems (d = 0.87) after an average of 13.6
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sessions.39 These effects were maintained at six-month
follow-up. Four patients with stable bipolar disorder were
offered a five-session modified format of ISTDP based on en-
hancing emotional awareness.35 At termination, BSI scores
had entered the nonclinical range, andmean IIP scores were
reduced but remained above the clinical cutoff.
Therapists in Training
Abbass38 reported data on a series of treatments provided by
psychiatry residents in videotape supervision. In this sam-
ple, the BSI-GSI improved significantly, to below the clinical
threshold, but self-rated interpersonal problems (IIP) did
not improve significantly (p = 0.10).39
Cost-Effectiveness
In total, nine identified studies provided cost-effectiveness
data16,34,36,39,41,42,44,54,55 (see Table 2). As noted, a very short
course of ISTDP preceded a 69% drop in emergency visit
costs, equating to a net U.S.$504 cost reduction per patient,
whereas controls had a nonsignificant increase in costs.43,55
In two naturalistic studies, reduced use of hospital andmen-
tal health services was reported. In the first (n = 89), which
had a high rate of personality disorders, the cost of hos-
pital services dropped by 85%, and the cost of physicians
by 33%, one year post-treatment.34 Further cost savings
accrued over the second- and third-year follow-ups.54 In
the second study (n = 93), hospital admissions and mental
health appointments dropped significantly.36 In five studies,
reducedmedication usage was reported.15/16,34,39,41,42 Signif-
icant reductions in medication usage were found in ISTDP-
treated groups versusminimal-contact controls (p= 0.001)41
and a treatment-as-usual group (p = 0.01).16 Large savings
from reduced disability claims were reported in five differ-
ent studies:34,39,41,42,44 the proportion returning to work after
a course of therapy ranged from 32.9%44 to 100%.42
Meta-analysis
Inclusion of studies. From the 21 studies identified in the
search, 427,34,36,42 were excluded from the meta-analysis be-
cause patient data from larger cohort studies were already
included. Two studies were excluded because they reported
data on the ISTDP trial therapy session alone15,16 and there-
fore could not be considered representative of a course of
ISTDP treatment. One study was excluded because no com-
mon outcome measure was available for comparison,33 and
another because ISTDP was provided as a combined treat-
ment alongside medication.30 In total, 13 studies compris-
ing 664 participants were included in the meta-analysis.
The mean number of participants per study in the ISTDP
treatment arm was 46.9 (range, 4–166). The average length
of treatment across studies was 19.7 sessions (SD = 16.3),
and 7 studies provided follow-up data averaging 15 months
(SD = 15). Given the wide variation in studies and patient
samples that were aggregated for this meta-analysis, the
results should be considered preliminary.
ISTDP pre- to post-treatment change. Pre to post mean pooled
effect sizes (d) for all outcome measures were large, ranging
from 0.84 to 1.51, indicating large improvements on mea-
sures of general psychopathology, depression, anxiety, and
interpersonal functioning. Significant heterogeneity was
seen in three of the four outcome categories, indicating re-
sults differed from study to study. See Table 3 for details.
We conducted sensitivity analyses in relation to general
psychopathology as the outcome measure. For RCTs, the
mean pooled effect size (d = 1.33; 95% CI, −0.44 to 3.09;
n = 2) was not significantly different than for nonrandom-
ized, controlled trials (d = 1.10; 95% CI, 0.77–1.42; n = 8)
(p = .80). In studies employing intention-to-treat analyses,
pre/post effect sizes on general psychopathology measures
were substantially higher (d = 2.03; 95% CI, 1.49–2.56;
n = 3) than in the group of studies employing completer-
only analyses (d = 0.96; 95% CI, 0.63–1.30; n = 8) (p ≤ .01).
In the subgroup of studies citing Davanloo 1990 or 2000, a
larger mean pooled effect size was found (d = 1.37; 95% CI,
0.97–1.77; n = 8) than in the subgroup of studies citing pre-
1990 publications by Davanloo (d = 0.58; 95% CI, 0.19–0.98;
n = 3). This difference was significant (p < .05).
ISTDP post-treatment to follow-up change. Post-treatment
to follow-up pooled effect sizes of general psychopathology
and interpersonal problems were found to be nonsignificant
(Table 3), indicating maintenance of gains. It must be noted,
however, that these analyses were based on a small number
of studies, and the finding of significant heterogeneity in
relation to general psychopathology indicates that results
differ from study to study. No post-treatment to follow-up
pooled mean effect sizes were calculated for depression and
anxiety (which were reported in only one and two studies,
respectively) as outcome measures.
ISTDP versus control conditions. ISTDP could be com-
pared to control groups at post-treatment in three studies
(Table 2). These included two with wait-list controls,11,28
and one with minimal treatment control.41 A large effect
size in favor of ISTDP versus controls was seen on mea-
sures of general psychopathology. No effect sizes for ISTDP
versus control conditions were calculated for the other out-
come measures, as relevant data were reported in one or
two studies only.
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Table 3. Meta-analyses of Studies Examining the Effects of ISTDP
Comparison n Cohen’s d 95% CI Z Q I2
Pre- vs. post-treatment
General psychopathology 11 1.16 0.82–1.50 6.71∗∗ 37.45∗∗ 73.30
Interpersonal functioning 7 0.84 0.50–1.18 4.83∗∗ 14.46∗ 58.50
Depression 5 1.51 1.16–1.87 8.37∗∗ 8.35 52.10
Anxiety 5 0.98 0.47–1.49 3.78∗∗ 26.21∗∗ 84.74
Post-treatment vs. follow-up
General psychopathology 4 0.01 −0.51 to 0.53 0.05 10.44∗ 71.28
Interpersonal functioning 3 0.12 −0.27 to 0.51 0.60 0.42 0.00
ISTDP vs. control groups post-treatment
General psychopathology 3 1.18 0.61–1.75 4.09∗∗ 4.70 57.44
CI, confidence interval; ISTDP, intensive short-term dynamic psychotherapy.
∗p < .05; ∗∗p < .01.
DISCUSSION
Based on these 21 studies conducted in several centers, it
is possible to draw some tentative conclusions about the
effects of ISTDP treatment. Subject to limitations of this
literature and the analyses conducted, the observed large
mean effects of treatment provide evidence that ISTDPmay
be effective for a wide range of patients. The preliminary
evidence also suggests that the method is cost-effective in
diverse populations.
The most compelling evidence for the efficacy of ISTDP is
in the treatment of personality disorders, as reflected in the
significant findings of improvement in three independent,
fairly rigorous RCTs. This evidence is corroborated by the
sustained benefits observed in several naturalistic studies.
ISTDP’s efficacy in other populations studied remains un-
certain due to a range of shortcomings in research methods
and the lack of replication.
The limitations of this body of research are signifi-
cant and notable. Studies are of variable quality, with
only a minority being RCTs and with many lacking ITT
analyses, adherence ratings, or independent evaluations
of outcome. Some of the studies appeared to employ
non-expert therapists who were in the process of learning
the approach—which is arguably not a good test of the
method. By contrast, many of these studies were conducted
by expert therapists—which may itself not reflect the
effectiveness of the method in the hands of a moderately
trained and experienced therapist. As with much of
psychotherapy research, the lack of clear tracking and
reporting on intervening psychosocial, medical, and self-
help treatments in most studies raises questions about the
causes of enduring treatment effects observed in follow-up.
The cost-effectiveness data from nine studies are likewise
unreliable because of the lack of complete reporting of
cost variables, among other methodological limitations
(Table 2).
One of the strengths of this body of research is the
diversity of centers, therapist experience, and patient
populations. Thus, these studies may reflect the clinical
“real world” of comorbidity and of clinicians with various
skill levels. Further, outcome data were largely based on
the use of standardized outcome measures, thus increasing
the potential replicability of the studies. Naturalistic
studies and RCT designs complement case-based re-
search, resulting in multiple levels of evidence for this
treatment.
We conducted a meta-analysis of this group of studies
in order to balance out effects resulting from differences
between therapists’ experience, countries, research centers,
and years in which the studies were undertaken (affecting
the particular model of ISTDP available at the time), and
thereby to gain a more accurate picture of the present body
of research. We found evidence of beneficial effects after-
versus-before ISTDP and between ISTDP and controls. In
the sensitivity analyses, the findings of greater effects when
ITT was performed and of no difference in effects between
RCTs and nonrandomized, controlled trials suggest that ob-
served benefits of ISTDP are not due to poor study qual-
ity. The finding of greater effects with the current version
of ISTDP compared to the pre-1990 iteration may reflect
a positive evolution of the therapy. These results must be
considered preliminary due to small numbers, diversity of
patient samples, variance in study quality, and heterogene-
ity in some analyses.
The effectiveness of the method with several somatic con-
ditions bears underscoring. Many patients who frequent
emergency departments and physician offices may benefit
from this approach, which appears to have effects across
neurological, immunological, musculoskeletal, and other
physical systems. These studies contribute to the growing
evidence base for short-term psychodynamic therapies in
diverse somatic conditions.4 The importance of reduced hos-
pital and physician costs after this brief therapy cannot be
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minimized in the current economic circumstances of most
international health care systems.
Some data suggest that the treatment can be used bene-
ficially in patients with dissociative disorders and more se-
vere personality disorders.11,41 It is notable that in one study,
patients with dissociative disorders appeared not to benefit
asmuch as those with other severe disorders;11 only one-half
to two-thirds responded when treated with this short-term
therapy. For better results with this particular population,
it may be that longer, but similar, interventions would need
to be used.56
Future research into ISTDP should include rigorous,
head-to-head comparisons versus more interpretative or
cognitive varieties of short-term psychodynamic psychother-
apy. The method should also be compared to other brief
models, such as cognitive-behavioral therapy,57 in the treat-
ment of specific populations. Blinded outcome ratings, RCT
design, ITT analyses, and moderately trained therapists
should be used in these studies. Finally, it would be helpful
to study the impact of training type (didactic versus su-
pervised) and quantity on the outcome of ISTDP in order to
characterize what training is required to deliver the method
effectively. In any event, given that studies have shown
good outcomes in the hands of trainees and early-career
therapists, it is reasonable to infer that that the method is
learnable.
The moderate amount of outcome research conducted by
Davanloo and subsequent researchers suggests that ISTDP
is a short, relatively inexpensive course of treatment that
may be both effective for, and applicable to, a broad range of
patient populations. Further rigorous, targeted research is
needed to answer questions about ISTDP’s scope of efficacy
and its cost-effectiveness.
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